Skip to Content

Theralink Technologies Inc Stock Quote THER

Rating as of

Morningstar's Theralink Technologies Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - THER

Company Profile - THER

Business Description

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented, phosphoprotein, and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Contact
15000 West 6th Avenue, Suite 400
Golden, CO, 80401
T +1 720 420-0074
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Sep 30, 2022
Stock Type Distressed
Employees 16